May-June 2019

Medical Plastic Data Service Magazine



Our 27th Year of Publication
Page  1 of 5


Cover Story

Drug Device Combination Products : Market Overview And Opportunities

Dr. Atul Sardana
Alfa Corpuscles Pvt. Ltd., New Delhi

Drug device combination products are defined as the individual products comprising of two regulated components, an active pharmaceutical ingredient and medical device that are chemically or physically combined to produce a “single product”. Some examples are drug eluting stents, prefilled syringes, bone graft implants, drug coated catheters, photodynamic / ionotophoretic therapy, wound care combination devices, inhalers, transdermal patches and drug eluting beads.

These products offer several advantages which include reduced adverse side effects, dose sparing, improved patient compliance, controlled release administration of drug, and also provide targeted drug delivery. Combination products have emerged as innovative medical products due to their contribution in advancing medical care and
are thus expected to have major impact on the overall medical devices market.

The global drug device combination products market was valued at USD 66 billion in 2012 and USD 96.3 billion in 2016, showing a growth at a CAGR of 7.9%, to reach an estimated value of USD 115 billion in 2019. Going further the market is expected to grow to about USD 140 billion by 2025.

The market is primarily driven by growing patient and physician preference for minimally invasive procedures and consistent-dosing treatment alternatives. The growth of the Global Drug-device Combination Products Market is driven by rise in incidence of chronic diseases such as diabetes, cancer, and respiratory problems, increase in casualties owing to accidents and trauma, rise in geriatric population, growth in homebased healthcare market, and technological advancements such as development of prefilled syringes. However, factors, such as unnoticed complications of drug-device combination products, number of product recalls, and stringent government regulations, hamper the market growth. Conversely, rise in healthcare infrastructure and high market potential in untapped emerging economies are expected to provide lucrative growth opportunities for the market.

The Subsequent increase in adoption of these products can be credited to associated benefits such as reduced pain levels, better patient outcome, reduced hospitals stay, and overall healthcare cost efficiency. Other advantages include synergistic effects facilitating multitarget treatment, improved tolerance levels, simplification of dosage regime, and improved symptomatic and pharmacokinetic profiles. These benefits are expected to propel demand for these systems and present the market with numerous growth opportunities.

In addition, frequent intervention by government health organizations to ensure high patient safety is also a predominant market driver.

Moreover, unprecedented growth in the development of clinical drugs and devices by large pharmaceutical companies is believed to meet the demand for advanced medication delivery technologies. This has resulted in extensive product pipelines and maximized commercial returns on already established products, thereby serving as a significant driving factor for the industry.

The global drug-device combination products market is segmented based on product, application, end user, and region. On the basis of product, the market is segmented into drug-eluting stent, infusion pump, photodynamic therapy, antimicrobial wound dressing, prefilled syringe, drug-eluting balloon, nebulizer, inhaler, transdermal delivery system, and others.

Drug-eluting stents are further sub-segmented into coronary stents and peripheral vascular stents. The infusion pumps segment is further divided into implantable infusion pump, insulin infusion pump, patient-controlled analgesia pump, and ambulatory infusion pump. Similarly, prefilled syringes are further categorized into single-chamber prefilled syringes, dual-chamber prefilled syringes, and customized prefilled syringes. The drug-eluting balloon segment is bifurcated into coronary drug-eluting balloon and peripheral drug-eluting balloon. The inhaler segment is further segmented into drug powder inhaler (DPI), metered dose inhaler (MDI), and soft mist inhaler (SMI). Lastly, the transdermal delivery system segment is bifurcated into passive delivery system and active delivery system.

The transdermal delivery system segment accounted for the largest market share in 2017 and is expected to continue this trend throughout the forecast period. Advantages associated with adoption of transdermal patches include better patient compliance and reduced risk of needlestick injuries and infections, which further accelerates demand for these patches. Moreover, rising patient preference for pain-free drug delivery has led to a significant surge in adoption of adhesive skin patches to administer drugs. This is expected to present the market with tremendous growth potential over the forecast period.

On the other hand, the prefilled syringe segment is anticipated to grow at a significant CAGR of 9.9% during the forecast period. This can be attributed to increasing demand for self administration of drugs in cases of diseases requiring long-term treatment. For instance, in diabetes, insulin is needed to be frequently administered intravenously into the patient’s body. This repeated use of injections to deliver insulin causes pain and increases risk of infection transmission, thus leading to heightened growth prospects for alternative drug delivery modes.

Advertisers' Index

Accuprec Research Labs Pvt. Ltd., India
Ambica Medicare Engineering, India
Nu-Vu Conair Pvt. Ltd., India
Divya Steri Solutions Pvt. Ltd., India
ET Elastomer Technik, Germany
Eewa Engineering Co. Pvt. Ltd., India
Ineos Styrolution India Ltd., India
I-Kare Polyalloys Pvt. Ltd., India
KLJ Group, India
Lubrizol Advanced Materials India Pvt. Ltd.
Kuraray India Pvt. Ltd., India
Maider Medical Industry Equipment Ltd.China
Medicall 2019, India
Ferromatik Milacron India Pvt. Ltd., India
GLR Laboratories Pvt. Ltd., India
Pashiba Lifescience, India
Plastivision India
Pradeep Surgipack, India
PVC Colouring Compounding & Processing, India
Qosina, USA
Raumedic AG
SMC Medical Manufacturing Pvt. Ltd., India
Sterimed Medical Devices (P) Ltd., India
Steri Techno Fab, India
Tekni-Plex India Pvt. Ltd., India
Twist Engineering Works,India
Yuhuan Shengjiu Mould Co., Ltd., China

Airways Surgical Pvt. Ltd., India

Alpha Medicare and Devices Ltd., India
Alpha Therapeutics Pvt. Ltd., India
Ami Polymer Pvt. Ltd., India
Angiplast Pvt. Ltd., India
Appasamy Associates, India
Beacon Plastics, India
Delux Surgical, Inida
Ignisol Mediplas Corporation, India
Jain Rubbers Pvt. Ltd., India
Operon Strategist, India
R.R. Patel Gases (P) Ltd., India

Proven Trade Contacts, India

Sanidhya Enterprise, India
Surgi Pack India Pvt. Ltd.
Unikal Consultants, India
Vinit Performance Polymers Pvt. Ltd., India
Aircity, India
Amigo Surgi Care Pvt. Ltd., India
Angel Products, India
Apex Medical Devices, India
Jimit Medico Surgicals Pvt. Ltd.
Kavya Packaging, India
Life-O-Line Technologist, India
Mesco Surgical, India
Morrisons Lifecare Pvt. Ltd., India
National Healthcare, India
Pharmadocx, Inida
S. Nath & Co., India
Unikal Consultants, India
Venus Industries,India, Mobile : 9825747495
Zinkal Products, India
Back | Back to Top  | Previous | Next